No Data
No Data
Express News | Avidity Biosciences Inc : BofA Global Research Raises Price Objective to $51 From $45
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating With New Price Objective
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
Express News | Avidity Biosciences Inc: Pricing of Upsized Underwritten Public Offering of 7.3 Mln Shares of Its Common Stock at a Price of $41.00 per Share
No Data
NVDAvsTSLA : Just one small interest rate cut made everyone happy![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
Sigma-Jobs : OK, very good